Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
6.60
+1.11 (20.22%)
At close: Aug 7, 2025, 4:00 PM
6.61
+0.01 (0.15%)
Pre-market: Aug 8, 2025, 7:17 AM EDT
Xeris Biopharma Holdings Revenue
Xeris Biopharma Holdings had revenue of $71.54M in the quarter ending June 30, 2025, with 48.84% growth. This brings the company's revenue in the last twelve months to $246.03M, up 35.62% year-over-year. In the year 2024, Xeris Biopharma Holdings had annual revenue of $203.07M with 23.89% growth.
Revenue (ttm)
$246.03M
Revenue Growth
+35.62%
P/S Ratio
4.09
Revenue / Employee
$624,429
Employees
394
Market Cap
1.06B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 203.07M | 39.16M | 23.89% |
Dec 31, 2023 | 163.91M | 53.67M | 48.68% |
Dec 31, 2022 | 110.25M | 60.66M | 122.32% |
Dec 31, 2021 | 49.59M | 29.16M | 142.67% |
Dec 31, 2020 | 20.44M | 17.71M | 650.73% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Novo Nordisk | 49.11B |
Eli Lilly and Company | 49.00B |
XERS News
- 12 hours ago - Xeris Biopharma Holdings, Inc. (XERS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance - Business Wire
- 8 days ago - Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025 - Business Wire
- 7 weeks ago - Xeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term Investing - Seeking Alpha
- 2 months ago - Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day - Business Wire
- 2 months ago - Xeris Announces Details for Analyst & Investor Day - Business Wire
- 3 months ago - Xeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Xeris Biopharma Reports Record First Quarter 2025 Financial Results - Business Wire